

CLNE0022: Skeletal Muscle and Associated Diseases

View Online



[1]

Ahmed, M. et al. 2016. Targeting protein homeostasis in sporadic inclusion body myositis. *Science Translational Medicine*. 8, 331 (Mar. 2016), 331ra41-331ra41. DOI:<https://doi.org/10.1126/scitranslmed.aad4583>.

[2]

Amato, A.A. and Greenberg, S.A. 2013. Inflammatory Myopathies. *CONTINUUM: Lifelong Learning in Neurology*. 19, (Dec. 2013), 1615-1633. DOI:<https://doi.org/10.1212/01.CON.0000440662.26427.bd>.

[3]

Atherton, P.J. and Smith, K. 2012. Muscle protein synthesis in response to nutrition and exercise. *The Journal of Physiology*. 590, 5 (Mar. 2012), 1049-1057. DOI:<https://doi.org/10.1113/jphysiol.2011.225003>.

[4]

Atherton, P.J. and Smith, K. 2012. Muscle protein synthesis in response to nutrition and exercise. *The Journal of Physiology*. 590, 5 (Mar. 2012), 1049-1057. DOI:<https://doi.org/10.1113/jphysiol.2011.225003>.

[5]

Baar, K. 2014. Using Molecular Biology to Maximize Concurrent Training. *Sports Medicine*. 44, S2 (Nov. 2014), 117-125. DOI:<https://doi.org/10.1007/s40279-014-0252-0>.

[6]

Baar, K. 2014. Using Molecular Biology to Maximize Concurrent Training. *Sports Medicine*. 44, S2 (Nov. 2014), 117–125. DOI:<https://doi.org/10.1007/s40279-014-0252-0>.

[7]

Baioni, M.T.C. and Ambiel, C.R. 2010. Spinal muscular atrophy: diagnosis, treatment and future prospects. *Jornal de Pediatria*. 86, 4 (Aug. 2010), 261–270. DOI:<https://doi.org/10.2223/JPED.1988>.

[8]

Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - *European Journal of Physical and Rehabilitation Medicine* 2013 April;49(2):169-78 - *Minerva Medica - Journals*: <https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169>.

[9]

Barohn, R.J. et al. 2014. A Pattern Recognition Approach to Patients with a Suspected Myopathy. *Neurologic Clinics*. 32, 3 (Aug. 2014), 569–593. DOI:<https://doi.org/10.1016/j.ncl.2014.04.008>.

[10]

Berthelsen, M.P. et al. 2014. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. *Neuromuscular Disorders*. 24, 6 (Jun. 2014), 492–498. DOI:<https://doi.org/10.1016/j.nmd.2014.03.001>.

[11]

Boldrin, L. et al. 2015. Satellite cells from dystrophic muscle retain regenerative capacity. *Stem Cell Research*. 14, 1 (Jan. 2015), 20–29. DOI:<https://doi.org/10.1016/j.scr.2014.10.007>.

[12]

Boldrin, L. and Morgan, J.E. 2007. Activating muscle stem cells: therapeutic potential in muscle diseases. *Current Opinion in Neurology*. 20, 5 (Oct. 2007), 577–582.
DOI:<https://doi.org/10.1097/WCO.0b013e3282ef5919>.

[13]

Briggs, D. and Morgan, J.E. 2013. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. *FEBS Journal*. 280, 17 (Sep. 2013), 4281–4293.
DOI:<https://doi.org/10.1111/febs.12273>.

[14]

Bushby, K. et al. 2014. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle & Nerve*. 50, 4 (Oct. 2014), 477–487.
DOI:<https://doi.org/10.1002/mus.24332>.

[15]

Bushby, K. et al. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *The Lancet Neurology*. 9, 1 (Jan. 2010), 77–93. DOI:[https://doi.org/10.1016/S1474-4422\(09\)70271-6](https://doi.org/10.1016/S1474-4422(09)70271-6).

[16]

Bushby, K. et al. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *The Lancet Neurology*. 9, 2 (Feb. 2010), 177–189. DOI:[https://doi.org/10.1016/S1474-4422\(09\)70272-8](https://doi.org/10.1016/S1474-4422(09)70272-8).

[17]

By:Gordon, AM (Gordon, AM); Homsher, E (Homsher, E); Regnier, M (Regnier, M) 2000. Regulation of contraction in striated muscle. *PHYSIOLOGICAL REVIEWS* *PHYSIOLOGICAL REVIEWS*. 80, 2 (2000), 853–924.

[18]

By:Jones, SW (Jones, SW); Hill, RJ (Hill, RJ); Krasney, PA (Krasney, PA); O'Conner, B (O'Conner, B); Peirce, N (Peirce, N); Greenhaff, PL (Greenhaff, PL) 2004. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes

associated with the regulation of skeletal muscle mass. *FASEB JOURNAL* FASEB JOURNAL. 18, 6 (2004). DOI:<https://doi.org/10.1096/fj.03-1228fje>.

[19]

Carstens, P.-O. and Schmidt, J. 2014. Diagnosis, pathogenesis and treatment of myositis: recent advances. *Clinical & Experimental Immunology*. 175, 3 (Mar. 2014), 349–358. DOI:<https://doi.org/10.1111/cei.12194>.

[20]

Cirak, S. et al. 2011. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *The Lancet*. 378, 9791 (Aug. 2011), 595–605. DOI:[https://doi.org/10.1016/S0140-6736\(11\)60756-3](https://doi.org/10.1016/S0140-6736(11)60756-3).

[21]

Craig, D.M. et al. 2015. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. *Frontiers in Physiology*. 6, (Oct. 2015). DOI:<https://doi.org/10.3389/fphys.2015.00296>.

[22]

Cup, E.H. et al. 2007. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. *Archives of Physical Medicine and Rehabilitation*. 88, 11 (Nov. 2007), 1452–1464. DOI:<https://doi.org/10.1016/j.apmr.2007.07.024>.

[23]

Dalakas, M.C. 2015. Inflammatory Muscle Diseases. *New England Journal of Medicine*. 372, 18 (Apr. 2015), 1734–1747. DOI:<https://doi.org/10.1056/NEJMra1402225>.

[24]

Darras, B.T. et al. 2003. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach. Butterworth-Heinemann.

[25]

Department of Health 2003. Toolkit for Producing Patient Information, Version 2. Crown copyright.

[26]

Dubowitz, V. et al. 2013. Muscle biopsy: a practical approach. Saunders Elsevier.

[27]

Egner, I.M. et al. 2013. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. *The Journal of Physiology*. 591, 24 (Dec. 2013), 6221–6230. DOI:<https://doi.org/10.1113/jphysiol.2013.264457>.

[28]

Feingold, B. et al. 2017. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation*. 136, 13 (Sep. 2017). DOI:<https://doi.org/10.1161/CIR.0000000000000526>.

[29]

Fitts, R.H. et al. 2010. Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. *The Journal of Physiology*. 588, 18 (Sep. 2010), 3567–3592. DOI:<https://doi.org/10.1113/jphysiol.2010.188508>.

[30]

Forbes, S.C. et al. 2014. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. *PLoS ONE*. 9, 9 (Sep. 2014). DOI:<https://doi.org/10.1371/journal.pone.0106435>.

[31]

Fuglsang-Frederiksen, A. 2006. The role of different EMG methods in evaluating myopathy.

Clinical Neurophysiology. 117, 6 (Jun. 2006), 1173–1189.
DOI:<https://doi.org/10.1016/j.clinph.2005.12.018>.

[32]

Garner, M. et al. 2012. A framework for the evaluation of patient information leaflets. Health Expectations. 15, 3 (Sep. 2012), 283–294.
DOI:<https://doi.org/10.1111/j.1369-7625.2011.00665.x>.

[33]

Glover, G.H. and Schneider, E. 1991. Three-point dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magnetic Resonance in Medicine. 18, 2 (Apr. 1991), 371–383. DOI:<https://doi.org/10.1002/mrm.1910180211>.

[34]

Goemans, N.M. et al. 2011. Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy. New England Journal of Medicine. 364, 16 (Apr. 2011), 1513–1522.
DOI:<https://doi.org/10.1056/NEJMoa1011367>.

[35]

Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). Stationery Office.

[36]

Hardie, D.G. and Sakamoto, K. 2006. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. Physiology. 21, 1 (Feb. 2006), 48–60.
DOI:<https://doi.org/10.1152/physiol.00044.2005>.

[37]

Harridge, S.D.R. et al. 1996. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. Pflügers Archiv - European Journal of Physiology. 432, 5 (Sep. 1996), 913–920. DOI:<https://doi.org/10.1007/s004240050215>.

[38]

Hawley, J.A. et al. 2014. Integrative Biology of Exercise. *Cell*. 159, 4 (Nov. 2014), 738–749.
DOI:<https://doi.org/10.1016/j.cell.2014.10.029>.

[39]

Hoffmann, G.F. et al. eds. 2017. *Inherited metabolic diseases: a clinical approach*. Springer.

[40]

Hogrel, J.-Y. et al. 2016. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. *Neurology*. 86, 11 (Mar. 2016), 1022–1030.
DOI:<https://doi.org/10.1212/WNL.0000000000002464>.

[41]

Hoier, B. and Hellsten, Y. 2014. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. *Microcirculation*. 21, 4 (May 2014), 301–314.
DOI:<https://doi.org/10.1111/micc.12117>.

[42]

Hollak, C.E.M. and Lachmann, R. eds. 2016. *Inherited Metabolic Disease in Adults*. Oxford University Press.

[43]

Hollak, C.E.M. and Lachmann, R. eds. 2016. *Inherited Metabolic Disease in Adults*. Oxford University Press.

[44]

Hollingsworth, K.G. et al. 2012. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France.

Neuromuscular Disorders. 22, (Oct. 2012), S54–S67.
DOI:<https://doi.org/10.1016/j.nmd.2012.06.005>.

[45]

Hunter, S. et al. 1998. Techniques to Evaluate Elderly Human Muscle Function: A Physiological Basis. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 53A, 3 (May 1998), B204–B216. DOI:<https://doi.org/10.1093/gerona/53A.3.B204>.

[46]

Institute of Neurology, Queen Square and National Hospital for Neurology and Neurosurgery (London, England) 2016. *Neurology: a Queen Square textbook*. John Wiley & Sons, Inc.

[47]

Jeppesen, T.D. et al. 2006. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. *Brain*. 129, 12 (Jun. 2006), 3402–3412.
DOI:<https://doi.org/10.1093/brain/awl149>.

[48]

Jones, D.A. et al. 2004. *Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine*. Churchill Livingstone.

[49]

Kadi, F. 2008. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. *British Journal of Pharmacology*. 154, 3 (Jun. 2008), 522–528.
DOI:<https://doi.org/10.1038/bjp.2008.118>.

[50]

Kim, H.K. et al. 2015. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping—Comparison Between Boys With Duchenne Muscular Dystrophy

and Healthy Boys. *American Journal of Roentgenology*. 205, 2 (Aug. 2015), W216–W223.
DOI:<https://doi.org/10.2214/AJR.14.13755>.

[51]

Kinali, M. et al. 2009. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *The Lancet Neurology*. 8, 10 (Oct. 2009), 918–928. DOI:[https://doi.org/10.1016/S1474-4422\(09\)70211-X](https://doi.org/10.1016/S1474-4422(09)70211-X).

[52]

Machado, P. et al. 2013. Update in inclusion body myositis. *Current Opinion in Rheumatology*. 25, 6 (Nov. 2013), 763–771.
DOI:<https://doi.org/10.1097/01.bor.0000434671.77891.9a>.

[53]

Machado, P.M. et al. 2014. Ongoing Developments in Sporadic Inclusion Body Myositis. *Current Rheumatology Reports*. 16, 12 (Dec. 2014).
DOI:<https://doi.org/10.1007/s11926-014-0477-9>.

[54]

Machado, P.M. et al. 2014. Sporadic inclusion body myositis. *Current Opinion in Neurology*. 27, 5 (Oct. 2014), 591–598. DOI:<https://doi.org/10.1097/WCO.0000000000000129>.

[55]

Marcotte, G.R. et al. 2015. The Molecular Basis for Load-Induced Skeletal Muscle Hypertrophy. *Calcified Tissue International*. 96, 3 (Mar. 2015), 196–210.
DOI:<https://doi.org/10.1007/s00223-014-9925-9>.

[56]

Matthews, E. and Hanna, M.G. 2014. Skeletal muscle channelopathies. *Oxford Textbook of Neuromuscular Disorders*. D. Hilton-Jones and M.R. Turner, eds. Oxford University Press. 316–325.

[57]

Mendell, J.R. et al. 2013. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Annals of Neurology*. 74, 5 (Nov. 2013), 637–647. DOI:<https://doi.org/10.1002/ana.23982>.

[58]

Mendell, J.R. et al. 2016. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Annals of Neurology*. 79, 2 (Feb. 2016), 257–271. DOI:<https://doi.org/10.1002/ana.24555>.

[59]

Mercuri, E. et al. 2012. Childhood spinal muscular atrophy: controversies and challenges. *The Lancet Neurology*. 11, 5 (May 2012), 443–452. DOI:[https://doi.org/10.1016/S1474-4422\(12\)70061-3](https://doi.org/10.1016/S1474-4422(12)70061-3).

[60]

Miguel A Martín 2014. Glycogen Storage Disease Type V. *Gene Reviews*. (2014).

[61]

Muntoni, F. et al. 2003. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *The Lancet Neurology*. 2, 12 (Dec. 2003), 731–740. DOI:[https://doi.org/10.1016/S1474-4422\(03\)00585-4](https://doi.org/10.1016/S1474-4422(03)00585-4).

[62]

Nancy D Leslie 2018. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. *Gene Reviews*. (2018).

[63]

Nancy Leslie 2017. Pompe Disease. *Gene Reviews*. (2017).

[64]

Needham, M. and Mastaglia, F.L. 2016. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. *Clinical Neurophysiology*. 127, 3 (Mar. 2016), 1764–1773.
DOI:<https://doi.org/10.1016/j.clinph.2015.12.011>.

[65]

Neuromuscular Disease Center: <https://neuromuscular.wustl.edu/>.

[66]

O'Brien, T.D. et al. 2010. In vivo measurements of muscle specific tension in adults and children. *Experimental Physiology*. 95, 1 (Jan. 2010), 202–210.
DOI:<https://doi.org/10.1113/expphysiol.2009.048967>.

[67]

Olivé, M. et al. 2013. Myofibrillar myopathies. *Current Opinion in Neurology*. 26, 5 (Oct. 2013), 527–535. DOI:<https://doi.org/10.1097/WCO.0b013e328364d6b1>.

[68]

Olpin, S.E. et al. 2015. The investigation and management of metabolic myopathies. *Journal of Clinical Pathology*. 68, 6 (Jun. 2015), 410–417.
DOI:<https://doi.org/10.1136/jclinpath-2014-202808>.

[69]

Ørngreen, M.C. and Vissing, J. 2017. Treatment Opportunities in Patients With Metabolic Myopathies. *Current Treatment Options in Neurology*. 19, 11 (Nov. 2017).
DOI:<https://doi.org/10.1007/s11940-017-0473-2>.

[70]

Paganoni, S. and Amato, A. 2013. Electrodiagnostic Evaluation of Myopathies. *Physical*

Medicine and Rehabilitation Clinics of North America. 24, 1 (Feb. 2013), 193–207.
DOI:<https://doi.org/10.1016/j.pmr.2012.08.017>.

[71]

Puthuchery, Z.A. et al. 2013. Acute Skeletal Muscle Wasting in Critical Illness. JAMA. 310, 15 (Oct. 2013). DOI:<https://doi.org/10.1001/jama.2013.278481>.

[72]

Rennie, M.J. et al. 2004. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 66, 1 (Mar. 2004), 799–828.
DOI:<https://doi.org/10.1146/annurev.physiol.66.052102.134444>.

[73]

Rennie, M.J. et al. 2004. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 66, 1 (Mar. 2004), 799–828.
DOI:<https://doi.org/10.1146/annurev.physiol.66.052102.134444>.

[74]

Ricotti, V. et al. 2013. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry. 84, 6 (Jun. 2013), 698–705.
DOI:<https://doi.org/10.1136/jnnp-2012-303902>.

[75]

Ross, J. et al. 2012. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. STEM CELLS. 30, 10 (Oct. 2012), 2330–2341. DOI:<https://doi.org/10.1002/stem.1197>.

[76]

Rudnik-Schöneborn, S. et al. 2001. The Predictive Value of Achieved Motor Milestones Assessed in 441 Patients with Infantile Spinal Muscular Atrophy Types II and III. European Neurology. 45, 3 (2001), 174–181. DOI:<https://doi.org/10.1159/000052118>.

[77]

Russman, B.S. et al. 1996. Function changes in spinal muscular atrophy II and III. *Neurology*. 47, 4 (Oct. 1996), 973–976. DOI:<https://doi.org/10.1212/WNL.47.4.973>.

[78]

Saudubray, J.M. et al. eds. 2016. *Inborn metabolic diseases: diagnosis and treatment*. Springer.

[79]

Schröder, R. and Schoser, B. 2009. Myofibrillar Myopathies: A Clinical and Myopathological Guide. *Brain Pathology*. 19, 3 (Jul. 2009), 483–492. DOI:<https://doi.org/10.1111/j.1750-3639.2009.00289.x>.

[80]

Shavlakadze, T. and Grounds, M. 2006. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. *BioEssays*. 28, 10 (Oct. 2006), 994–1009. DOI:<https://doi.org/10.1002/bies.20479>.

[81]

Sveen, M.-L. et al. 2013. Resistance training in patients with limb-girdle and becker muscular dystrophies. *Muscle & Nerve*. 47, 2 (Feb. 2013), 163–169. DOI:<https://doi.org/10.1002/mus.23491>.

[82]

Thomas Wieser 2017. Carnitine Palmitoyltransferase II Deficiency. *Gene Reviews*. (2017).

[83]

Velloso, C.P. 2008. Regulation of muscle mass by growth hormone and IGF-I. *British Journal of Pharmacology*. 154, 3 (Jun. 2008), 557–568. DOI:<https://doi.org/10.1038/bjp.2008.153>.

[84]

Voet, N.B. et al. 2013. Strength training and aerobic exercise training for muscle disease. Cochrane Database of Systematic Reviews. (Jul. 2013). DOI:<https://doi.org/10.1002/14651858.CD003907.pub4>.

[85]

Wang, C.H. et al. 2007. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *Journal of Child Neurology*. 22, 8 (Aug. 2007), 1027–1049. DOI:<https://doi.org/10.1177/0883073807305788>.

[86]

Wattjes, M.P. and Fischer, D. 2013. *Neuromuscular imaging*. Springer.

[87]

Wiggs, M.P. 2015. Can endurance exercise preconditioning prevention disuse muscle atrophy? *Frontiers in Physiology*. 6, (Mar. 2015). DOI:<https://doi.org/10.3389/fphys.2015.00063>.

[88]

Willcocks, R.J. et al. 2016. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. *Annals of Neurology*. 79, 4 (Apr. 2016), 535–547. DOI:<https://doi.org/10.1002/ana.24599>.

[89]

Zammit, P.S. et al. 2004. Muscle satellite cells adopt divergent fates. *The Journal of Cell Biology*. 166, 3 (Aug. 2004), 347–357. DOI:<https://doi.org/10.1083/jcb.200312007>.

[90]

1983. An information leaflet for surgical patients. *Annals of The Royal College of Surgeons of England*. 65, 4 (1983).

[91]

1996. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. *The Journal of Physiology*. 495, Pt 2 (1996).

[92]

Neuropathology and Applied Neurobiology. Volume 43, Issue 1.

[93]

1983. Prescription information leaflets: a pilot study in general practice. *British Medical Journal (Clinical research ed.)*. 287, 6400 (1983).